|
|
|
Unique Collection of Therapeutic Antibody Technologies. XOMA has a unique collection of eight of the leading commercial antibody phage display libraries in addition to related antibody optimization and expression technologies (Table 1). This collection of antibody discovery and development technologies was established through strategic cross-licensing of XOMA's enabling expression technology and innovation at XOMA. The benefits translate to an increased probability of success, reduced cost and shorter development timelines. For our partners, XOMA represents a single point of access for enhancing their competitive position in therapeutic antibodies  | |
Increased Probability of Success. Each phage display library has a unique repertoire of over 10 billion different human antibodies. A benefit of having access to multiple libraries, each with a unique diversity, is the ability to screen libraries in parallel. This increases the probability of finding rare functional antibodies that meet or exceed design goals based on medical and commercial objectives tailored to each target. An added advantage is flexibility to select an exclusive or nonexclusive library for antibody discovery to the target of interest. With this comprehensive collection of libraries, customized antibody discovery strategies and an experienced scientific staff, XOMA rapidly identifies therapeutic antibodies with desired properties, shortening time to IND filing and clinical evaluation.
|
©XOMA 2008